Junichi Tomomatsu

691 total citations
49 papers, 431 citations indexed

About

Junichi Tomomatsu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Junichi Tomomatsu has authored 49 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 15 papers in Otorhinolaryngology. Recurrent topics in Junichi Tomomatsu's work include Head and Neck Cancer Studies (15 papers), Sarcoma Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Junichi Tomomatsu is often cited by papers focused on Head and Neck Cancer Studies (15 papers), Sarcoma Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Junichi Tomomatsu collaborates with scholars based in Japan, United States and India. Junichi Tomomatsu's co-authors include Shunji Takahashi, Kenji Nakano, Makiko Ono, Naoki Fukuda, Yasuyoshi Sato, Tetsuya Urasaki, Akihiro Ohmoto, Xiaofei Wang, Hiroki Mitani and Mayu Yunokawa and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Annals of Oncology.

In The Last Decade

Junichi Tomomatsu

45 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junichi Tomomatsu Japan	13	232	158	106	68	64	49	431
Carrie B. Marshall United States	11	140 0.6×	129 0.8×	94 0.9×	81 1.2×	25 0.4×	20	397
Salma Alam United Kingdom	10	143 0.6×	160 1.0×	91 0.9×	66 1.0×	13 0.2×	14	332
Juliette Haudebourg France	14	206 0.9×	268 1.7×	144 1.4×	112 1.6×	105 1.6×	37	651
Tetsuya Urasaki Japan	12	205 0.9×	107 0.7×	73 0.7×	55 0.8×	33 0.5×	53	416
Soo Chin Canada	6	256 1.1×	189 1.2×	185 1.7×	68 1.0×	148 2.3×	10	536
Rambha Pandey India	10	181 0.8×	160 1.0×	69 0.7×	48 0.7×	9 0.1×	50	397
Takehisa Hashimoto Japan	15	230 1.0×	372 2.4×	130 1.2×	36 0.5×	26 0.4×	42	647
Hui‐Ping Chien Taiwan	12	141 0.6×	76 0.5×	152 1.4×	52 0.8×	13 0.2×	18	368
Soichi Oka Japan	13	159 0.7×	260 1.6×	89 0.8×	20 0.3×	12 0.2×	59	453
Dušica Gavrilović Serbia	13	185 0.8×	91 0.6×	72 0.7×	36 0.5×	7 0.1×	54	352

Countries citing papers authored by Junichi Tomomatsu

Since Specialization

Citations

This map shows the geographic impact of Junichi Tomomatsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junichi Tomomatsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junichi Tomomatsu more than expected).

Fields of papers citing papers by Junichi Tomomatsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junichi Tomomatsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junichi Tomomatsu. The network helps show where Junichi Tomomatsu may publish in the future.

Co-authorship network of co-authors of Junichi Tomomatsu

This figure shows the co-authorship network connecting the top 25 collaborators of Junichi Tomomatsu. A scholar is included among the top collaborators of Junichi Tomomatsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junichi Tomomatsu. Junichi Tomomatsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fukuda, Naoki, Kazuhisa Toda, Ryosuke Oki, et al.. (2024). Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine Journal. 71(4). 363–371. 1 indexed citations

Fukuda, Naoki, Ryosuke Oki, Xiaofei Wang, et al.. (2023). Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck. Oncology. 101(8). 502–511. 1 indexed citations

Ohmoto, Akihiro, Kenji Nakano, Naoki Fukuda, et al.. (2023). Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study. PLoS ONE. 18(3). e0280508–e0280508. 1 indexed citations

Fujiwara, Yu, Yasuyoshi Sato, Naomi Hayashi, et al.. (2023). The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin. Journal of Geriatric Oncology. 14(5). 101523–101523. 5 indexed citations

Fukuda, Naoki, Kazuhisa Toda, Akihiro Ohmoto, et al.. (2022). A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients. Endocrine. 76(1). 70–77. 6 indexed citations

Ariyasu, Ryo, Mitsutomi Ishiyama, Toshiaki Mochizuki, et al.. (2022). Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging. International Cancer Conference Journal. 12(2). 109–114. 2 indexed citations

Takahashi, Shunji, Yutaka Fujiwara, Kenji Nakano, et al.. (2021). Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science. 112(6). 2361–2370. 43 indexed citations

Sato, Yasuyoshi, Kenji Nakano, Xiaofei Wang, et al.. (2021). Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers. 13(24). 6266–6266. 10 indexed citations

Sato, Yasuyoshi, Naoki Fukuda, Yu Fujiwara, et al.. (2021). Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer. In Vivo. 35(2). 1211–1215. 14 indexed citations

10.

Fukuda, Naoki, Kazuhisa Toda, Akihiro Ohmoto, et al.. (2021). Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Anticancer Research. 41(3). 1683–1691. 7 indexed citations

11.

Sato, Yukiko, Naoki Fukuda, Tetsuya Urasaki, et al.. (2020). Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial. SHILAP Revista de lepidopterología. 1 indexed citations

12.

Fukuda, Naoki, Mayu Yunokawa, Yu Fujiwara, et al.. (2020). Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer Reports. 4(2). e1322–e1322. 7 indexed citations

13.

Nakano, Kenji, Keiko Hayakawa, Yuki Funauchi, et al.. (2020). Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Molecular and Clinical Oncology. 14(1). 13–13. 6 indexed citations

14.

Sato, Yasuyoshi, Naoki Fukuda, Xiaofei Wang, et al.. (2020). <p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p>. Cancer Management and Research. Volume 12. 4161–4168. 12 indexed citations

15.

Fukuda, Naoki, Kazuhisa Toda, Yu Fujiwara, et al.. (2020). Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib. In Vivo. 34(5). 2859–2864. 21 indexed citations

16.

Watanabe, Naoki, Hajime Yasuda, Soji Morishita, et al.. (2017). Richter’s Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide. Case Reports in Oncology. 10(1). 123–126. 6 indexed citations

17.

Takahashi, Shunji, Takayuki Kobayashi, Junichi Tomomatsu, et al.. (2016). LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. Cancer Chemotherapy and Pharmacology. 79(1). 131–138. 11 indexed citations

18.

Nakano, K, Shannon Marshall, Yasunori Sato, et al.. (2016). A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab. Annals of Oncology. 27. vi346–vi346. 1 indexed citations

19.

Nakano, Kenji, Noriko Motoi, Lina Inagaki, et al.. (2015). Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. Japanese Journal of Clinical Oncology. 45(5). 449–455. 12 indexed citations

20.

Tomomatsu, Junichi, Yasushi Isobe, Kazuo Oshimi, et al.. (2010). Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutatedIGHgene, and indolent clinical behavior. Leukemia & lymphoma. 51(12). 2230–2239. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact